WAVE LIFE SCIENCES LTD. Proceeds from Issuance of Warrants
WAVE LIFE SCIENCES LTD. (WVE) reported Proceeds from Issuance of Warrants of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2025-11-10
- WAVE LIFE SCIENCES LTD. proceeds from issuance of warrants for the quarter ending 2022-12-31 was -$4.00K.
- WAVE LIFE SCIENCES LTD. proceeds from issuance of warrants for the quarter ending 2022-09-30 was -$64.00K.
- WAVE LIFE SCIENCES LTD. proceeds from issuance of warrants for fiscal 2022 was $14.27M.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | |||
| 2024-09-30 | $14.10M 10-Q · filed 2025-11-10 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$68.00K derived: sum of 2 quarters · filed 2024-03-06 | $14.27M 10-K · filed 2024-03-06 | |
| 2022-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.27M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $14.34M 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |